(E/Z)-Zotiraciclib citrate

• CAT Number: I043964
• CAS Number: 1204918-73-9
• Molecular Formula: C29H32N4O8
• Molecular Weight: 564.59
• Purity: ≥95%
• Synonyms: 2-hydroxypropane-1,2,3-tricarboxylic acid;(16E)-14-methyl-20-oxa-5,7,14,27-tetrazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene
• InChI: InChI=1S/C23H24N4O.C6H8O7/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27;7-3(8)1-6(13,5(11)12)2-4(9)10/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b3-2+
• InChIKey: NWYDRHSNEATNRI-SQQVDAMQSA-N
• SMILES: CN1C/C=C/CCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

(E/Z)-Zotiraciclib citrate（Cat No.:I043964）is a potent oral cyclin-dependent kinase (CDK) inhibitor, targeting CDK9 and other transcription-regulating kinases involved in cancer cell proliferation and survival. It exists as a mixture of E and Z isomers and is formulated as a citrate salt to enhance solubility and stability. By inhibiting CDK9, (E/Z)-Zotiraciclib disrupts transcriptional elongation, downregulates anti-apoptotic proteins like Mcl-1, and induces apoptosis in tumor cells. It has shown promise in preclinical and early clinical studies, particularly for glioblastoma and other solid tumors, supporting its development as a targeted anticancer agent.